Antacids Market (By Dosage Form: Tablet, Liquid, Others; By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Published at : January-2019 | Delivery Format : PDF | Status: Published | Pages : 160


The global antacids market size is expected to around USD 8.4 billion by 2026, this market is foreseen to develop with 4.4% CAGR during the forecast time period.

Market Dynamics

Changing dietary propensities is one of the main considerations expected to fuel the development forthcoming years. Also irregular eating and sleeping patterns are the other region which may drive acidy in the population, which is projected to drive the growth of the market.

Expanding commonness of Gastro Esophageal Reflux Diseases (GERD) is relied upon to influence the general market over the forthcoming years. As per the Gut journal, distributed by the International Foundation for Gastrointestinal Disorders; in 2017, the pervasiveness of GERD was around 18% to 28% in North America, 9% to 26% in Europe, 3% to 8% in East Asia, 9% to 33% in Middle East, 12% in Australia, and 23% in South America.

Market Insights

Tablet was evaluated to be the biggest segment in 2018. Nearness of chewable tablets in various flavors enhances quiet adherence to the drug, which thusly is required to add to development of the portion. Tablets can give the correct measure of dose to the patients contrasted with other dose structures and they are anything but difficult to store. These components can be credited to the segment development over the forthcoming years. Other key drivers expected to encourage the segment development incorporate dispatch of new product by real players.

Fluid segment is relied upon to be the quickest developing portion in the general market forthcoming years. Nearness of key players, for example, Pfizer Inc.; GlaxoSmithKline plc. Furthermore, Dabur offering fluid acid neutralizer, is evaluated to help the segment development. Furthermore, fluid dose shape is one of favoured decisions for youngsters and older populace because of its acceptable taste. This factor is additionally foreseen to look good for market development.

Asia Pacific is required to be the biggest and quickest developing provincial segment amid the forthcoming years inferable from high neglected clinical necessities, accessibility of compelling treatment techniques, rising disposable income, and purchaser mindfulness about the accessibility of these product. Likewise, the nearness of key players, for example, Pfizer Inc.; GlaxoSmithKline plc.; Abbott is foreseen to develop the market over the forthcoming years. Enhancing healthcare system, and developing speculations by market players is relied upon to build its development.

Market Segmentation

Market By Dosage Form

  • Tablet
  • Liquid
  • Others

Market By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

North America is assessed to be the second biggest developing portion. This was credited to expanding stomach related confusion pervasiveness combined with purchaser attention to acid neutralizer product. In 2017, as indicated by the CDC, the quantity of visits in crisis offices with stomach related framework infections as the essential analysis was around 32.3 million. Moreover, the nearness of developed economies inside the region is adding fuel to its development in this region.

Market Participants

Few of the main businesses present in the global Antacids market are Procter & Gamble; laxoSmithKline plc; Pfizer Inc.; Bayer AG; Takeda Pharmaceutical Company Limited; BoehringerIngelheim International GmbH; Sun Pharmaceuticals Ltd.; Dr. Reddy’s Laboratories Ltd.; Reckitt Benckiser Group plc; and Sanofi.

Cart Summary